Literature DB >> 33235325

CDK4/6 inhibitors for HR+HER2- early stage breast cancer - when to escalate treatment?

Giuseppe Curigliano1,2.   

Abstract

Entities:  

Year:  2021        PMID： 33235325     DOI： 10.1038/s41571-020-00453-1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

Authors:  Stephen R D Johnston; Nadia Harbeck; Roberto Hegg; Masakazu Toi; Miguel Martin; Zhi Min Shao; Qing Yuan Zhang; Jorge Luis Martinez Rodriguez; Mario Campone; Erika Hamilton; Joohyuk Sohn; Valentina Guarneri; Morihito Okada; Frances Boyle; Patrick Neven; Javier Cortés; Jens Huober; Andrew Wardley; Sara M Tolaney; Irfan Cicin; Ian C Smith; Martin Frenzel; Desirée Headley; Ran Wei; Belen San Antonio; Maarten Hulstijn; Joanne Cox; Joyce O'Shaughnessy; Priya Rastogi
Journal:  J Clin Oncol       Date:  2020-09-20       Impact factor: 50.717
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.